Corrigendum: The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation (Oncogene (2012) 32 (1691-1701) DOI: 10.1038/onc.2012.182);The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation

Oncogene

Volumn 32, Issue 13, 2013, Pages 1691-1701

  Das, C M ^a   Taylor, P ^a   Gireud, M ^a   Singh, A ^a   Lee, D ^a   Fuller, G ^a   Ji, L ^a   Fangusaro, J ^b   Rajaram, V ^b   Goldman, S ^b   Eberhart, C ^c   Gopalakrishnan, V ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Deubiquitylase; p27; Proliferation; REST; USP37

Indexed keywords

CYCLIN DEPENDENT KINASE; PEPTIDASE; PROTEIN P27; REGULATOR PROTEIN; REST PROTEIN; UNCLASSIFIED DRUG; USP37 PROTEIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; UBIQUITINATION; WILD TYPE;

EID: 84875908346     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.141     Document Type: Erratum

References (72)

1. Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC et al. REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995; 80: 949-957.
2. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): A coordinate repressor of multiple neuron-specific genes. Science 1995; 267: 1360-1363.
3. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005; 121: 645-657.
4. Ballas N, Mandel G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr Opin Neurobiol 2005; 15: 500-506.
5. Hsieh J, Gage FH. Chromatin remodeling in neural development and plasticity. Curr Opin Cell Biol 2005; 17: 664-671.
6. Ooi L, Wood IC. Chromatin crosstalk in development and disease: Lessons from REST. Nat Rev Genet 2007; 8: 544-554.
7. Kagalwala MN, Singh SK, Majumder S. Stemness is only a state of the cell. Cold Spring Harb Symp Quant Biol 2008; 73: 227-234.
8. Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS One 2009; 4: E7936.
9. Juliandi B, Abematsu M, Nakashima K. Chromatin remodeling in neural stem cell differentiation. Curr Opin Neurobiol 2010; 20: 408-415.
10. Gopalakrishnan V. REST and the RESTless: In stem cells and beyond. Future Neurol 2009; 4: 317-329.
11. Gao Z, Ure K, Ding P, Nashaat M, Yuan L, Ma J et al. The master negative regulator REST/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells. J Neurosci 2011; 31: 9772-9786.
12. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med 2000; 6: 826-831.
13. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G et al. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol 2006; 26: 1666-1678.
14. Fuller GN, Su X, Price RE, Cohen ZR, Lang FF, Sawaya R et al. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther 2005; 4: 343-349.
15. Miyazawa K, Himi T, Garcia V, Yamagishi H, Sato S, Ishizaki Y. A role for p27/Kip1 in the control of cerebellar granule cell precursor proliferation. J Neurosci 2000; 20: 5756-5763.
16. Goto T, Mitsuhashi T, Takahashi T. Altered patterns of neuron production in the p27 knockout mouse. Dev Neurosci 2004; 26: 208-217.
17. Zindy F, Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF. N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proc Natl Acad Sci USA 2006; 103: 11579-11583.
18. Bhatia B, Northcott PA, Hambardzumyan D, Govindarajan B, Brat DJ, Arbiser JL et al. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: Separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res 2009; 69: 7224-7234.
19. Bhatia B, Malik A, Fernandez LA, Kenney AM. p27(Kip1), a double-edged sword in Shh-mediated medulloblastoma: Tumor accelerator and suppressor. Cell Cycle 2010; 9: 4307-4314.
20. Bhatia B, Nahle Z, Kenney AM. Double trouble: When sonic hedgehog signaling meets TSC inactivation. Cell Cycle 2010; 9: 456-459.
21. Ayrault O, Zindy F, Rehg J, Sherr CJ, Roussel MF. Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res 2009; 7: 33-40.
22. Todi SV, Paulson HL. Balancing act: Deubiquitinating enzymes in the nervous system. Trends Neurosci 2011.
23. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009; 78: 363-397.
24. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.
25. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 2006; 66: 8655-8661.
26. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002; 16: 2699-2712.
27. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13: 41-47.
28. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199.
29. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-4699.
30. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449.
31. Hara T, Kamura T, Kotoshiba S, Takahashi H, Fujiwara K, Onoyama I et al. Role of the UBL-UBA protein KPC2 in degradation of p27 at G1 phase of the cell cycle. Mol Cell Biol 2005; 25: 9292-9303.
32. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004; 6: 1229-1235.
33. Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J 2007; 26: 2562-2574.
34. Kotoshiba S, Kamura T, Hara T, Ishida N, Nakayama KI. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem 2005; 280: 17694-17700.
35. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9: 2400-2411.
36. Ungermannova D, Gao Y, Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem 2005; 280: 30301-30309.
37. Masuda K, Ishikawa Y, Onoyama I, Unno M, de Alboran IM, Nakayama KI et al. Complex regulation of cell-cycle inhibitors by Fbxw7 in mouse embryonic fibroblasts. Oncogene 2010; 29: 1798-1809.
38. Wilkinson KD. DUBs at a glance. J Cell Sci 2009; 122(Part 14): 2325-2329.
39. Komander D, Clague MJ, Urbe S. Breaking the chains: Structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
40. Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, Chapman M et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci USA 2004; 101: 10458-10463.
41. Sun YM, Cooper M, Finch S, Lin HH, Chen ZF, Williams BP et al. Rest-mediated regulation of extracellular matrix is crucial for neural development. PLoS One 2008; 3: E3656.
42. Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T et al. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 2008; 452: 365-369.
43. Chang L, Schwarzenbach H, Meyer-Staeckling S, Brandt B, Mayr GW, Weitzel JM et al. Expression regulation of the metastasis-promoting protein InsP3-kinase-A in tumor cells. Mol Cancer Res 2011.
44. Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. PLoS One 2009; 4: E7665.
45. Kohyama J, Sanosaka T, Tokunaga A, Takatsuka E, Tsujimura K, Okano H et al. BMP-induced REST regulates the establishment and maintenance of astrocytic identity. J Cell Biol 2010; 189: 159-170.
46. Ravanpay AC, Hansen SJ, Olson JM. Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation. Mol Cell Neurosci 2010; 44: 178-189.
47. Tomasoni R, Negrini S, Fiordaliso S, Klajn A, Tkatch T, Mondino A et al. A signaling loop of REST, TSC2 and {beta}-catenin governs proliferation and function of PC12 neural cells. J Cell Sci 2011; 124(Pt 18): 3174-3186.
48. Wander SA, Zhao D, Slingerland JM. p27: A barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2011; 17: 12-18.
49. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
50. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G et al. Cyclin-dependent kinases: A family portrait. Nat Cell Biol 2009; 11: 1275-1276.
51. Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008; 7: 892-898.
52. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
53. Kaldis P. Another piece of the p27Kip1 puzzle. Cell 2007; 128: 241-244.
54. Pagano M. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 2004; 14: 414-416.
55. Reed SI. Keeping p27(Kip1) in the cytoplasm: A second front in cancer's war on p27. Cell Cycle 2002; 1: 389-390.
56. Koff A. How to decrease p27Kip1 levels during tumor development. Cancer Cell 2006; 9: 75-76.
57. Huang X, Summers MK, Pham V, Lill JR, Liu J, Lee G et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell 2011; 42: 511-523.
58. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008; 452: 370-374.
59. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B et al. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005; 121: 837-848.
60. Spencer EM, Chandler KE, Haddley K, Howard MR, Hughes D, Belyaev ND et al. Regulation and role of REST and REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiol Dis 2006; 24: 41-52.
61. Coulson JM. Transcriptional regulation: Cancer, neurons and the REST. Curr Biol 2005; 15: R665-R668.
62. Pereg Y, Liu BY, O'Rourke KM, Sagolla M, Dey A, Komuves L et al. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat Cell Biol 2010; 12: 400-406.
63. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789.
64. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 2007; 104: 8869-8874.
65. Peschiaroli A, Skaar JR, Pagano M, Melino G. The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene 2010; 29: 1384-1393.
66. McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF et al. The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res 2010; 70: 3329-3339.
67. van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH. Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle 2008; 7: 2710-2719.
68. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011; 60: 3-11.
69. Hayes SD, Cdc25A Harper JW. and Dub3 in a high-stakes balancing act. Nat Cell Biol 2010; 12: 311-313.
70. Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009; 93: 303-318.
71. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G et al. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(beta-TRCP) in neuroblastoma cells. Cancer 2011; 117: 5189-5202.
72. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D et al. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 2010; 46: 2771-2780.